bop

BOP is anantagonist of alpha4beta1/alpha9beta1 integrins. BOP rapidly mobilizes long-term multi-lineage reconstituting hematopoietic stem cells (HSC).

I-BOP is an agonist (KD=0.61 nM) at the thromboxane A2 receptor (TP). I-BOP promotes cell proliferation by activating the PI3K pathway in vascular smooth muscle.

BOP-JF549 is a fluorescent dual α9β1/α4β1 integrin inhibitor. Comprises BOP conjugated to Janelia Fluor® 549. Fluorogenic: fluoresces only once bound to integrins, enabling hassle-free no-wash experiments. Bright and photostable, enabling live cell tracking of integrin receptors over long time-course experiments. Excitation maximum = 549 nm; emission maximum = 571 nm.

BOP-JF646 is a fluorescent dual α9β1/α4β1 integrin inhibitor. Comprises BOP conjugated to Janelia Fluor®646. Fluorogenic: fluoresces only once bound to integrins, enabling hassle-free no-wash experiments. Bright and photostable, enabling live cell tracking of integrin receptors over long time-course experiments. Excitation maximum = 655 nm; emission maximum = 672 nm.

BOP sodium salt is an inhibitor of alpha9beta1 and alpha4beta1 integrin.

Totrombopag (SB559448) is a candidate compound for action on RSV polymerase.

Carboplatin (JM-8) is a cisplatin derivative, a DNA synthesis inhibitor. Carboplatin binds to DNA, inhibits replication and transcription, and induces cell death. Carboplatin has antitumor activity.

TBOPP is a selective DOCK1 inhibitor (IC50 : 8.4 μM), with anti-tumor activity for broader types of tumors.

Hetrombopag olamine is a non-peptide thrombopoietin (TPO) receptor agonist with oral activity.

Kobophenol A has antimicrobial, and anti-inflammatory activities, it might be a candidate for treatment of inflammatory bone diseases relevant to osteoblast cell death. Kobophenol A inhibits AChE activity in a dose-dependent manner, and the IC50 value is

(E/Z)-Eltrombopag 13C4 ((E/Z)-SB-497115 13C4) is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled. Z-Eltrombopag is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.

Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.

Bopindolol ((±)-Bopindolol) fumarate is an orally active β-adrenoceptor (ARs) antagonist with partial agonist activity that is non-selective for β1- and β2-ARs and has low affinity for the β3-AR subtype. Bopindolol fumarate is a precursor drug to Pindolol and can be used to study primary and renal vascular hypertension.

Hetrombopag is a potent agonist of the thrombopoietin receptor. Hetrombopag is well tolerated and has a controlled safety profile. hetrombopag has potential for studies in immune thrombocytopenia.

Eltrombopag Olamine (Eltrombopag diethanolamine salt) is the orally active ethanolamine salt of eltrombopag, a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production.

Avatrombopag, also known as AKR-501, YM477, AS 1670542 or E5501, is a novel orally-active thrombopoietin (TPO) receptor agonist. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501 may be useful in the treatment of patients with thrombocytopenia. Avatrombopag was first approved in 2018.

Lusutrombopag (Mulpleta) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.

Ebopiprant (OBE022) is an orally available, selective and potent prostaglandin F2α (PGF2α) receptor antagonist that interferes with the binding of PGF0126α to the FPR and can be used in the study of obesity.

Lusutrombopag-d13 is a deuterated compound of Lusutrombopag. Lusutrombopag has a CAS number of 1110766-97-6. Lusutrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.

Bopindolol is a non-selective β-adrenergic receptor antagonist. In vivo, bopindolol decreases heart rate and blood pressure and attenuates ischemia-induced myocardial acidosis in dogs. Formulations containing bopindolol have been used to treat essential and renovascular hypertension.

Rafutrombopag is a thrombopoietin (TPO) agonist.

Ebopiprant, also known as OBE-022, is an Oral and Selective Prostaglandin F 2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor. OBE022 exhibits potent tocolytic effects on human tissues ex vivo and animal models in vivo without causing the adverse fetal side effects seen with indomethacin.

Totrombopag, also known LGD-4665, GSK2285921 and SB559448, is an oral thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies.

Carboprost (15(S)-15-Methyl Prostaglandin F2α) is a synthetic prostaglandin analogue of PGF2α which has the effect of oxytocic. Carboprost is commonly used to restore uterine tone.

Fluoroclebopride is a dopamine (DA) D2 receptor ligand.

Avatrombopag hydrochloride (AKR-501) is an orally active, nonpeptide agonist of the thrombopoietin (TPO) receptor with an EC 50 of 3.3 nM. It effectively mimics the biological activities of TPO, stimulating platelet production by activating the intracellular signaling system and facilitating the generation of platelets and megakaryocytes from hemopoietic precursor cells. Additionally, Avatrombopag hydrochloride serves as a substrate for cytochrome P450 (CYP) 2C9 and CYP3A.

Sibopirdine is a new type of cognitive enhancer and intelligence booster that has been studied as a cognitive enhancer for the treatment of Alzheimer's disease.

Bopindolol is an orally active antagonist of β-adrenoceptors (ARs) with partial agonist activity. Bopindolol is non-selective for β1- and β2-ARs and has low affinity for β3-AR subtype. Bopindolol is a prodrug of pindolol and can be rapidly metabolized to an active hydrolyzed form. Bopindolol can be used for essential and renovascular hypertension research [1] [2].

TCPOBOP is a constitutive androstane receptor agonist that induces robust hepatocyte proliferation and hepatomegaly. TCPOBOP decreases Fas-induced murine liver injury by altering Bcl-2 proteins.

Avatrombopag-d8 is a deuterated compound of Avatrombopag. Avatrombopag has a CAS number of 570406-98-3. Avatrombopag is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.

Carboplatin-d4 is a deuterated compound of Carboplatin. Carboplatin has a CAS number of 41575-94-4. Carboplatin is an organoplatinum compound that possesses antineoplastic activity.

Clebopride malate is a dopamine antagonist drug Used to treat functional gastrointestinal disorders such as nausea or vomiting.

Eltrombopag Methyl Ester, a derivative of Eltrombopag, functions as a thrombopoietin (Tpo) receptor agonist to enhance platelet production and is employed in the study of certain thrombocytopenia variants.

Carboprost tromethamine, a synthetic 15-methyl analogue of prostaglandin F2α, effectively promotes uterine contractions and significantly reduces bleeding during and post-delivery.

Eltrombopag (SB-497115-GR), an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity, binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110).

Clebopride is antidopaminergic. Clebopride also has an effect of antiemetic.

R-BC154 is a high affinity fluorescent α4β1/α9β1 inhibitor (Kdvalues are 12.7 and 38 nM, respectively); fluorescent version of BOP. Rapidly and preferentially mobilizes HSCs and progenitorsin vivo. Excitation maximum, 561 nm; emissiosn maximum, 585 nm.

8-iso PGE2 is one of several isoprostanes produced from arachidonic acid during lipid peroxidation. It is a potent renal vasoconstrictor in the rat. 8-iso PGE2 inhibits U-46619 or I-BOP-induced platelet aggregation with IC50 values of 0.5 and 5 μM, respectively. When infused into the renal artery of the rat at a concentration of 4 μg/kg/min, 8-iso PGE2 decreases the GFR and renal plasma flow by 80% without affecting blood pressure.

Bid BH3 (80-99) is a biologically active peptide known as a pro-apoptotic member of the 'BH3-only' (BOPS) subset within the BCL-2 protein family, pivotal in apoptosis regulation. It notably interacts with Bcl-2, Bax, and Bak, initiating their activation or inactivation, thus inducing cell death. Additionally, Bid translocates from the cytosol to the mitochondrial membrane as part of its functional mechanism. The presence of Pyroglutamyl (pGlu) peptides, which can spontaneously arise from Glutamine (Q) or Glutamic acid (E) at the N-terminus of sequences, is a natural process. The hydrophobic γ-lactam ring of pGlu is theorized to enhance peptide stability, providing resistance to gastrointestinal proteases, making these peptides a recognized variant within peptide analyses, including HPLC purity assessments.